Syndax Pharmaceuticals (SNDX)
(Delayed Data from NSDQ)
$14.78 USD
-0.67 (-4.34%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $14.77 -0.01 (-0.07%) 4:26 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Syndax Pharmaceuticals, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
SNDX 14.78 -0.67(-4.34%)
Will SNDX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SNDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNDX
Wall Street Analysts Believe Syndax (SNDX) Could Rally 112.8%: Here's is How to Trade
Agilent Q3 Earnings Beat Estimates, Revenues Up Y/Y, Shares Rise
SNDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates
All You Need to Know About Syndax (SNDX) Rating Upgrade to Buy
Other News for SNDX
BTIG Reiterates Buy Rating on SNDX with $56 Price Target | SNDX Stock News
3 Potential Biotech Acquisition Targets
Is SNDX signaling a buying opportunity? Pocket Pivot shows up after advancing 4.75%
SNDX: Revumenib Gains Key NCCN Recommendation for AML Treatment
Syndax announces updated NCCN Guidelines for AML